Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Early experience with T-cell receptor cellular therapy in advanced solid malignancies: A multi-center analysis of safety and efficacy. This is an ASCO Meeting Abstract from the 2026 ASCO Annual ...

MSNPseq: An NGS-based assay for chimerism detection and risk assessment in allogeneic HSCT. Pharmacogenetic (PGx) markers of cardiovascular side effects (CVSEs) in allogeneic hematopoietic cell ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...

CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

Viruses are effective tools for delivering genetic material into cells, and scientists have taken advantage of viral transduction in numerous ways, such as constructing chimeric antigen receptor (CAR) ...